SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luis a. garcia who wrote (700)11/11/1997 9:59:00 AM
From: MCorbley  Read Replies (1) of 1115
 
Luis, Charles

Glad to be of service. I forgot to add another thought about Lidakol's competitors:
In a head-to-head clinical trial in Europe, Lidakol compared favorably with Zovirax 5% cream for treatment of cold sores. Zovirax 5% cream is better than anything available in the U.S., in particular Zovirax 5% ointment. Yamanouchi has invested a great deal of money and effort in testing and developing Lidakol for the European market. Therefore they must believe that there is still an unaddressed need for Lidakol and a market for Lidakol even in Europe despite the availability of Zovirax cream.

Michael
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News